MSB 2.78% $2.45 mesoblast limited

Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-458

  1. 23,522 Posts.
    lightbulb Created with Sketch. 1660
    I think its quite obviously now the tiny upfront for a global deal is because of the TYPE A meeting with FDA.

    As you said, this would have been months in the making, co-incidence TUES feedback resulted in the deal Friday?

    On manufacturing, (KEY as you have said, and I have said for years)
    all the cheerleaders here have not acknowledged the 3D and new media is going to start in pre-clinical.

    No way in heck its coming for ARDs.

    and the other issue is Covid/ARDs is the same product they just rejected for GvHD, and a likely No in Type A meeting.
    Last edited by Sector: 22/11/20
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Mkt cap ! $1.439B
Open High Low Value Volume
$2.50 $2.51 $2.44 $7.265M 2.948M

Buyers (Bids)

No. Vol. Price($)
41 208165 $2.45

Sellers (Offers)

Price($) Vol. No.
$2.46 29440 2
View Market Depth
Last trade - 16.10pm 15/01/2021 (20 minute delay) ?
-0.070 ( 1.46 %)
Open High Low Volume
$2.50 $2.50 $2.44 902562
Last updated 15.59pm 15/01/2021 (live) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.